Complete pathological response and negative postoperative ctDNA were not predictive of discontinuation of adjuvant crizotinib therapy in a patient with locally advanced MET ex14 skipping mutation-positive non-small cell lung cancer: a case report.

Wang, Jiantao; Yao, Wenqing; Wang, Weiya; Fan, Mingyu; Huang, Kaili; Liu, Zhenkun; Zhu, Daxing

Wang, Jiantao; Yao, Wenqing; Wang, Weiya; Fan, Mingyu; Huang, Kaili; Liu, Zhenkun; Zhu, Daxing.

Afiliación

Wang J; Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yao W; Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Wang W; Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Fan M; Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Huang K; Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Liu Z; Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhu D; Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Front Oncol ; 13: 1164543, 2023.

Article en En | MEDLINE | ID: mdl-37554169

Palabras clave

MET exon 14 skipping mutation; NSCLC; case report; crizotinib rechallenge; neoadjuvant targeted therapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google